Cargando…
Lysophosphatidic acid and its receptors LPA(1) and LPA(3) mediate paclitaxel-induced neuropathic pain in mice
BACKGROUND: Paclitaxel, which is widely used for the treatment of solid tumors, causes neuropathic pain via poorly understood mechanisms. Previously, we have demonstrated that lysophosphatidic acid (LPA) and its receptors (LPA(1) and LPA(3)) are required for the initiation of peripheral nerve injury...
Autores principales: | Uchida, Hitoshi, Nagai, Jun, Ueda, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246549/ https://www.ncbi.nlm.nih.gov/pubmed/25411045 http://dx.doi.org/10.1186/1744-8069-10-71 |
Ejemplares similares
-
Phosphorylation and Internalization of Lysophosphatidic Acid Receptors LPA(1), LPA(2), and LPA(3)
por: Alcántara-Hernández, Rocío, et al.
Publicado: (2015) -
Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain
por: Inoue, Makoto, et al.
Publicado: (2008) -
An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model
por: Ma, Lin, et al.
Publicado: (2013) -
Lysophosphatidic acid LPA(1) and LPA(3) receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice
por: Ueda, Hiroshi, et al.
Publicado: (2018) -
Recent advances in understanding of various chronic pain mechanisms through lysophosphatidic acid (LPA) receptor signaling
por: Ueda, Hiroshi
Publicado: (2012)